ALK and colorectal carcinoma: Subsequently, the survival analysis showed BRAF/ALK (NOTCH2, CREBBP, or FAT1) were associated with shorter PFS (p = 0.17, Figure 5B) and OS (p = 0.019, Figure 5C) in CRC patients.